Research Topics
Species | Robert VonderheideSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Telomerase-based immunotherapy of cancerErica L Carpenter
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII/III, 421 Curie Blvd, Philadelphia, PA 19104, USA
Expert Opin Biol Ther 6:1031-9. 2006..Immunotherapy induces functional, antitumour T cells in patients in the absence of clinical toxicity. The opportunity for vaccinating individuals as an immunoprevention strategy can also be envisioned for hTERT-based therapies...- Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomeraseR H Vonderheide
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 7:3343-8. 2001..The applicability of hTERT as a potential target for anticancer immunotherapy would be widened by the identification of epitopes restricted to other common HLA alleles, such as HLA-A3 antigen... - Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide
Abramson Family Cancer Research Institute, Abramson Cancer Center, Division of Hematology Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Clin Oncol 25:876-83. 2007..CD40 is also expressed by solid tumors, but its engagement results in apoptosis. CP-870,893, a fully human and selective CD40 agonist monoclonal antibody (mAb), was tested for safety in a phase I dose-escalation study... 
Prospects and challenges of building a cancer vaccine targeting telomeraseRobert H Vonderheide
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
Biochimie 90:173-80. 2008....- Universal tumor antigens for cancer vaccination: targeting telomerase for immunopreventionRobert H Vonderheide
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Discov Med 7:103-8. 2007.... - Prospect of targeting the CD40 pathway for cancer therapyRobert H Vonderheide
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
Clin Cancer Res 13:1083-8. 2007.... - A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapyRobert H Vonderheide
Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center and the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Immunol Res 27:341-56. 2003..Phase I trials translating these discoveries to novel active and passive T cell therapies have been initiated, with an eye toward combining these strategies once safety is established... - Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individualsR H Vonderheide
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 61:8366-70. 2001..These findings support clinical efforts to target the hTERT as a tumor antigen with broad therapeutic potential... - RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapyChristina M Coughlin
Division of Hematology and Oncology, Children's Hospital of Philadelphia, and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 19104, USA
Blood 103:2046-54. 2004..These findings support a novel platform for tumor-specific vaccine or adoptive immunotherapies in pediatric malignancies... - Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical applicationMichael S von Bergwelt-Baildon
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Blood 99:3319-25. 2002..Therefore, they are an excellent source of professional APCs for immune assessment, antigen discovery, and antigen-specific immunotherapy... - Interferon beta adenoviral gene therapy in a patient with ovarian cancerDaniel H Sterman
Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA
Nat Clin Pract Oncol 3:633-9. 2006..Diagnosis Stage IV ovarian cancer with malignant ascites and pleural effusion.Management Tunneled pleural catheter and intrapleural adenoviral-mediated interferon beta gene therapy... - A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responsesDaniel H Sterman
Thoracic Oncology Gene Therapy Program and Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, PA 19104 4283, USA
Clin Cancer Res 13:4456-66. 2007..IFN-beta) in patients with malignant pleural mesothelioma (MPM) and metastatic pleural effusions (MPE)... - Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulationErica L Carpenter
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Transl Med 7:93. 2009.... - Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERTDih Yih Chen
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Biol Ther 6:1991-6. 2007..Thus, I540-specific T cells can vary in cytotoxic potential depending on the method of generation, isolation and expansion... - A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusionsDaniel H Sterman
Section of Interventional Pulmonology and Thoracic Oncology, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104 4283, USA
Mol Ther 18:852-60. 2010..This approach was safe, induced immune responses and disease stability. However, rapid development of Nabs prevented effective gene transfer after the second dose, even with a dose interval as short as 7 days... - Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinomaPeter DeLong
Thoracic Oncology Research Laboratory, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer Biol Ther 4:342-6. 2005..These results have implications for the development of immunotherapy directed to the malignant pleural space, and suggest the need to tailor immunotherapy to overcome immunosuppressive mechanisms in tumor environments... - Telomerase as a universal tumor-associated antigen for cancer immunotherapyRobert H Vonderheide
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
Oncogene 21:674-9. 2002..Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun that test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer... - Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patientsGwenn Aël H Danet-Desnoyers
Division of Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Exp Hematol 33:1275-80. 2005.... - Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillanceSusan M Domchek
Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Cancer Res 67:10546-55. 2007..These results suggest that hTERT-specific T cells could contribute to the immunosurveillance of breast cancer and suggest novel opportunities for both therapeutic and prophylactic vaccine strategies for cancer... - Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancersErica L Carpenter
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Cancer Res 15:4277-87. 2009..This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers... 
Telomerase as a universal tumor antigen for cancer vaccinesGregory L Beatty
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII III, 421 Curie Boulevard, Philadelphia, PA 19104, USA
Expert Rev Vaccines 7:881-7. 2008..Findings obtained from these trials will inform the possibility of broad-spectrum cancer immunotherapy or even immunoprevention...- Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cellsAndrew J Rech
Abramson Family Cancer Research Institute and the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Ann N Y Acad Sci 1174:99-106. 2009..If confirmed in additional patients, these observations suggest that daclizumab may be an effective and available therapeutic agent for Treg modulation in patients with cancer... - Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cellsRobert H Vonderheide
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Clin Cancer Res 16:3485-94. 2010..Tremelimumab is a fully human monoclonal antibody specific for CTL-associated antigen 4 (CTLA4) with single-agent activity in certain tumors but has not been evaluated in patients with breast cancer... - Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytesRobert H Vonderheide
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Clin Cancer Res 10:828-39. 2004..CONCLUSIONS: These results demonstrate the immunological feasibility of vaccinating patients against telomerase and provide rationale for targeting self-antigens with critical roles in oncogenesis... - Regulatory T cells: overcoming suppression of T-cell immunityTatiana N Golovina
Abramson Family Cancer Research Institute and the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Cancer J 16:342-7. 2010..More sophisticated techniques that have become available for Treg analysis in patients will assist in this important translational effort... - Cancer-testis antigens in tumor biology and immunotherapyCAROLYN E CLARK
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Cancer Biol Ther 5:1226-7. 2006 - Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexesCAROLYN E CLARK
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Clin Cancer Res 11:5333-6. 2005 - Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretionBrian J Czerniecki
Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Cancer Res 67:1842-52. 2007..DC1 vaccination strategies may therefore have potential for both the prevention and the treatment of early breast cancer... - Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destructionJan C Schmollinger
Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:3398-403. 2003..These findings demonstrate that ML-IAP can serve as a target for immune-mediated tumor destruction, but that antigen-loss variants can accomplish immune escape... - Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivoGregor S D Reid
Division of Oncology, Department of Pediatrics, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Clin Cancer Res 15:6602-8. 2009..To investigate the impact of interferon-gamma-mediated upregulation of major histocompatibility complex class I expression on tumor-specific T-cell cytotoxicity and T-cell trafficking into neuroblastoma tumors in vivo... - Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage displayRolf K Swoboda
Immunology Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
Cancer Res 67:3555-9. 2007..The RPL8 antigen may represent a relevant vaccine target for patients with melanoma, glioma, and breast carcinoma whose tumors express this protein... - Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis CDavid E Kaplan
Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
Gastroenterology 132:654-66. 2007..Although HCV-specific CD4 T-cell response is associated with HCV clearance, less is known about virus-specific CD8 T-cell or neutralizing antibody (nAb) responses and the role of CD4 help in their induction during acute infection... - Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantationGinna G Laport
Translational Research Program, Abramsonm Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Blvd, Philadelphia, PA 19104-6160, USA
Blood 102:2004-13. 2003.... - Viral antigen-specific CD8+ T-cell responses are impaired in multiple myelomaBritta Maecker
Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA
Br J Haematol 121:842-8. 2003..Prospective studies will determine whether such immune assessment strategies may identify patients more likely to benefit from cancer immunotherapy... - Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degenerationErica L Carpenter
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, United States
J Neuroimmunol 193:173-82. 2008..In contrast, viral-specific CD8(+) T cells from healthy volunteers and PCD patients were measurable. These findings are inconsistent with an obligate role for cdr2-1- or cdr2-2-specific CD8(+) T cells in the pathogenesis of PCD... - HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapyAntonio Scardino
, Institut Gustave Roussy, Villejuif, France
J Immunol 168:5900-6. 2002..These results suggest that heteroclitic variants of low affinity, cryptic epitopes of widely expressed tumor Ags may serve as valid tools for tumor immunotherapy... - The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cellsBritta Maecker
Head, Molecular Tumor Biology and Tumor Immunology University of Cologne, Joseph Stelzmann Str 9 Haus 16, 50924 Cologne, Germany
Blood 102:3287-94. 2003..These findings form the basis of a phase 1 clinical trial exploring a DNA-based vector encoding CYP1B1 for widely applicable cancer immunotherapy conducted at the Dana-Farber Cancer Institute... - Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modalityChristina M Coughlin
Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania USA
Cancer Biol Ther 2:466-70. 2003.... - High vaccination efficiency of low-affinity epitopes in antitumor immunotherapyDavid Alexandre Gross
Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Gustave Roussy, Villejuif, France
J Clin Invest 113:425-33. 2004..Our results strongly argue for new TAA epitope selection and modification strategies in antitumor immunotherapy applications in humans... - Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantationDaniel H Fowler
Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
Biol Blood Marrow Transplant 12:1150-60. 2006..Allograft augmentation with costimulated, IL-4-polarized donor CD4(+) T cells resulted in activated Th1, Th2, and inflammatory cytokine pathways without an apparent increase in GVHD...
Research Grants
- TELOMERASE AS A WIDELY EXPRESSED TUMOR ANTIGENRobert Vonderheide; Fiscal Year: 2004..Lee M. Nadler, a recognized leader in the field of tumor immunology with a strong track record for fostering the career development of physician-scientists. ..
- Immunoregulation and immunotherapy of breast cancerRobert Vonderheide; Fiscal Year: 2006..This trial will determine the effect of daclizumab on the disruption of Treg function and the effect of daclizumab on the immunogenicity of vaccine as well as clinical response of patients with breast cancer. ..
- Immunoregulation and immunotherapy of breast cancerRobert Vonderheide; Fiscal Year: 2007..This trial will determine the effect of daclizumab on the disruption of Treg function and the effect of daclizumab on the immunogenicity of vaccine as well as clinical response of patients with breast cancer. ..
- Immunoregulation and immunotherapy of breast cancerRobert H Vonderheide; Fiscal Year: 2010..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..